[Amiodarone and secondary prevention. The EMIAT study]

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Secondary prevention of mortality after myocardial infarction is crucial for high-risk patients.
• Left ventricular ejection fraction < 40% identifies patients at increased risk of mortality post-myocardial infarction.
• Amiodarone is an antiarrhythmic drug with potential benefits in secondary cardiac prevention.

Purpose of the Study:

• To evaluate the efficacy of amiodarone in preventing total mortality.
• To assess the benefit-risk ratio of amiodarone for secondary prevention in high-risk patients post-myocardial infarction.

Main Methods:

• Randomized, double-blind, placebo-controlled trial (EMIAT).
• Inclusion of patients with left ventricular ejection fraction < 40% post-myocardial infarction.
• Multicenter European study involving 3,400 patients.

Main Results:

• Efficacy of amiodarone in reducing total mortality was evaluated.
• Benefit-risk ratio of amiodarone for secondary prevention was assessed.

Conclusions:

• The study aimed to determine amiodarone's role in reducing mortality in a specific high-risk cardiac population.
• Findings contribute to the understanding of amiodarone's utility in post-myocardial infarction care.